B2AD-Risk AFDAS Evolution of Burden of AF

Launched by LONDON HEALTH SCIENCES CENTRE RESEARCH INSTITUTE OR LAWSON RESEARCH INSTITUTE OF ST. JOSEPH'S · Sep 6, 2024

Keywords

ClinConnect Summary

The B2AD-Risk AFDAS trial is studying how atrial fibrillation (AF) develops in patients who have experienced an ischemic stroke, which is a type of stroke caused by a blockage in a blood vessel supplying blood to the brain. This trial aims to understand how AF worsens over time in stroke patients, looking at factors like heart health and new risks such as high blood pressure. Researchers will monitor participants for up to 24 months to see how often AF occurs and if certain heart markers change, which could help improve treatments in the future.

To participate in this study, you must be an adult who has had a specific type of acute ischemic stroke, either with a known history of AF or newly diagnosed AF. You cannot participate if you have a permanent or persistent form of AF, or if you have allergies to certain contrast agents used in imaging. Participants will go through regular check-ups and tests to track their heart health and the progression of AF. This research could lead to better ways to prevent strokes and manage AF for those who have had a stroke.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients with cortical or subcortical, cryptogenic or non-cryptogenic acute ischemic stroke
• * Any of the following types of AF:
• • Paroxysmal AF known before stroke onset (KAF).
• • Paroxysmal AF found on an admission or Emergency Department ECG (ECG-AFDAS)
• • Paroxysmal AF found on 14-day Holter monitoring (PCM-AFDAS)
• Exclusion Criteria:
• • Patients not willing to consent
• • Permanent or persistent AF
• • Allergy to iodinated contrast agents